Clinical Trials
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is...
Clinical Trials
LSK Global PS Adopts Veeva Vault Clinical Applications to Streamline Global Trial Processes
Veeva Systems announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, LSK Global PS can streamline...
News
Vetter establishes office in China to better serve the needs of its growing customer base worldwide
Germany based Vetter, one of the global leaders in prefilled drug-delivery systems, has announced the opening of a new business entity in Shanghai, China. The new office, now its fourth in the Asia Pacific (APAC) region, will help increase...
News
Natco’s marketing partner gets USFDA nod for cancer treatment drug
Natco Pharma said its marketing partner Breckenridge Pharmaceutical Inc has received final approval from the US health regulator for cancer treatment drug Everolimus. The approved product is a generic for Afinitor.
"Breckenridge Pharmaceutical Inc (BPI) has received final approval for...
Drug Research
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.
With this expansion,...
News
Celonic to Boost its Cell & Gene Therapy Production with Facility in the upcoming Life Science Park Rheintal in Switzerland
Celonic Group, a leading global contract development and manufacturing organization (CDMO), specialized in development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office space spanning 91,500...
News
Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches
Aptamer Group, the developer of Optimer reagents and therapeutics, has announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company.
This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read